2022年度発表論文等一覧

原著論文－英文

1. Eiden J, Volckaert B, Rudenko O, Aitchison R, Herber R, Belshe R, Greenberg H, Coelingh K, Marshall D, Kawaoka Y, Neumann G, Bilsel P.
   Single Replication M2SR Influenza Vaccine Induced Immune Responses Associated with Protection Against Human Challenge with Highly Drifted H3N2 Influenza Strain.
   J Infect Dis 226(1):83-90, 2022.
2. Patania OM, Chiba S, Halfmann PJ, Hatta M, Maemura T, Bernard KA, Kawaoka Y, Crawford LK.
   Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats.
   Vet Pathol 59(4):696-706, 2022.
3. McLean HQ, McClure DL, King JP, Meece JK, Pattinson D, Neumann G, Kawaoka Y, Rolfes MA, Belongia EA.
   mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021.
   Influenza Other Respir Viruses 16(4):607-612, 2022.
4. Mizutani T, Ishizaka A, Koga M, Ikeuchi K, Saito M, Adachi E, Yamayoshi S, Iwatsuki-Horimoto K, Yasuhara A, Kiyono H, Matano T, Suzuki Y, Tsutsumi T, Kawaoka Y, Yotsuyanagi H.
   Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization.
   Microbiol Spectr 10(2):e0168921, 2022.
5. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y.
   Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
   N Engl J Med 386(15):1475-1477, 2022.
6. McMahan K, Giffin V, Tostanoski LH, Chung B, Siamatu M, Suthar MS, Halfmann P, Kawaoka Y, Piedra-Mora C, Jain N, Ducat S, Kar S, Andersen H, Lewis MG, Martinot AJ, Barouch DH.
   Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. Med (N Y).
   3(4):262-268.e4, 2022.
7. Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y.
   Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan.
   Intern Med 61(11):1681-1686, 2022.
8. Halfmann PJ, Kuroda M, Maemura T, Chiba S, Armbrust T, Wright R, Balaram A, Florek KR, Bateman AC, Kawaoka Y.
   Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters.
   Cell Rep 39(3):110688, 2022.
9. Ueki H, Ito M, Furusawa Y, Yamayoshi S, Inoue SI, Kawaoka Y.
   A 265-Nanometer High-Power Deep-UV Light-Emitting Diode Rapidly Inactivates SARS-CoV-2 Aerosols.
   mSphere 7:e0094121, 2022.
10. Okuda M, Sakai-Tagawa Y, Koga M, Koibuchi T, Kikuchi T, Adachi E, Lim LA, Yamamoto S, Yotsuyanagi H, Negishi K, Jubishi D, Yamayoshi S, Kawaoka Y.
    Immunological correlates of prevention of the onset of seasonal H3N2 influenza.
    J Infect Dis 226(10):1800-1808, 2022.
11. Chong Z, Karl CE, Halfmann PJ, Kawaoka Y, Winkler ES, Keeler SP, Holtzman MJ, Yu J, Diamond MS.
    Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron.
    Cell Rep 2022 39(6):110799, 2022.
12. Darling TL, Ying B, Whitener B, VanBlargan LA, Bricker TL, Liang CY, Joshi A, Bamunuarachchi G, Seehra K, Schmitz AJ, Halfmann PJ, Kawaoka Y, Elbashir SM, Edwards DK, Thackray LB, Diamond MS, Boon ACM.
    mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2.
    Med (N Y) 3(5):309-324.e6, 2022.
13. Halfmann PJ, Kuroda M, Armbrust T, Theiler J, Balaram A, Moreno GK, Accola MA, Iwatsuki-Horimoto K, Valdez R, Stoneman E, Braun K, Yamayoshi S, Somsen E, Baczenas JJ, Mitamura K, Hagihara M, Adachi E, Koga M, McLaughlin M, Rehrauer W, Imai M, Yamamoto S, Tsutsumi T, Saito M, Friedrich TC, O'Connor SL, O'Connor DH, Gordon A, Korber B, Kawaoka Y.
    Characterization of the SARS-CoV-2 B.1.621 (Mu) variant.
    Sci Transl Med eabm4908, 2022.
14. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y.
    Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
    Nature 607(7917):119-127, 2022.
15. Fisher T, Gluck A, Narayanan K, Kuroda M, Nachshon A, Hsu JC, Halfmann PJ, Yahalom-Ronen Y, Tamir H, Finkel Y, Schwartz M, Weiss S, Tseng CK, Israely T, Paran N, Kawaoka Y, Makino S, Stern-Ginossar N.
    Parsing the role of NSP1 in SARS-CoV-2 infection.
    Cell Rep 39(11):110954, 2022.
16. Belser JA, Lau EHY, Barclay W, Barr IG, Chen H, Fouchier RAM, Hatta M, Herfst S, Kawaoka Y, Lakdawala SS, Lee LYY, Neumann G, Peiris M, Perez DR, Russell C, Subbarao K, Sutton TC, Webby RJ, Yang H, Yen HL; Working group on the standardization of the ferret model for influenza risk assessment.
    Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise.
    mBio e0117422, 2022.
17. Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Whitener B, Guarino B, Schmid MA, Rosenthal K, Ren K, Dang HV, Snell G, Jung A, Droit L, Handley SA, Halfmann PJ, Kawaoka Y, Crowe JE Jr, Fremont DH, Virgin HW, Loo YM, Esser MT, Purcell LA, Corti D, Diamond MS.
    Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
    Nat Commun 13(1):3824, 2022.
18. Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yomayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H.
    Casirivimab/imdevimab for active COVID-19 pneumonia persisted for nine months in a patient with follicular lymphoma during anti-CD20 therapy.
    Jpn J Infect Dis 75(6):608-611, 2022.
19. Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N Engl J Med 387(5):468-470, 2022. 
20. Byrd-Leotis L, Jia N, Matsumoto Y, Lu D, Kawaoka Y, Steinhauer DA, Cummings RD.
    Sialylated and sulfated N-Glycans in MDCK and engineered MDCK cells for influenza virus studies.
    Sci Rep 12(1):12757, 2022.
21. Fan S, Gu C, Kong H, Guan L, Neumann G, Kawaoka Y.
    Influenza Viruses Suitable for Studies in Syrian Hamsters.
    Viruses. 14(8):1629, 2022.
22. Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y, Ito M, Uraki R, Halfmann P, Watanabe S, Takeda M, Hasegawa H, Imai M, Kawaoka Y.
    Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.
    N Engl J Med 387(13):1236-1238, 2022.
23. Uraki R, Kiso M, Imai M, Yamayoshi S, Ito M, Fujisaki S, Takashita E, Ujie M, Furusawa Y, Yasuhara A, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Watanabe S, Hasegawa H, Kawaoka Y.
    Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.
    1 in Syrian hamsters. Nat Microbiol 7(8):1252-1258, 2022.
24. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, Pinto D, VanBlargan LA, De Marco A, di Iulio J, Zatta F, Kaiser H, Noack J, Farhat N, Czudnochowski N, Havenar-Daughton C, Sprouse KR, Dillen JR, Powell AE, Chen A, Maher C, Yin L, Sun D, Soriaga L, Bassi J, Silacci-Fregni C, Gustafsson C, Franko NM, Logue J, Iqbal NT, Mazzitelli I, Geffner J, Grifantini R, Chu H, Gori A, Riva A, Giannini O, Ceschi A, Ferrari P, Cippà PE, Franzetti-Pellanda A, Garzoni C, Halfmann PJ, Kawaoka Y, Hebner C, Purcell LA, Piccoli L, Pizzuto MS, Walls AC, Diamond MS, Telenti A, Virgin HW, Lanzavecchia A, Snell G, Veesler D, Corti D.
    Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
    Nature 602(7898):664-670, 2022.
25. Ueki H, Ujie M, Komori Y, Kato T, Imai M, Kawaoka Y.
    Effectiveness of HEPA Filters at Removing Infectious SARS-CoV-2 from the Air.
    mSphere Aug 31;7(4):e0008622, 2022.
26. Eiden J, Volckaert B, Rudenko O, Aitchison R, Herber R, Belshe R, Greenberg H, Coelingh K, Marshall D, Kawaoka Y, Neumann G, Bilsel P.
    M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain J Infect Dis 226(1):83-90, 2022.
27. Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, Duong C, Hamabata T, Ito M, Chiba S, Kobayashi R, Takahashi S, Mitamura K, Hagihara M, Shibata A, Uwamino Y, Hasegawa N, Ebina T, Izumi A, Kato H, Nakajima H, Sugaya N, Seki Y, Iqbal A, Kamimaki I, Yamazaki M, Kawaoka Y, Furuse Y.
    Age-stratified seroprevalence of antibodies against SARS-CoV-2 in the pre- and post-vaccination era, February 2020–March 2022, Japan.
    Emerg Infect Dis 28(11):2198-2205, 2022.
28. Koga M, Iwatsuki-Horimoto K, Kikuchi T, Yamayoshi S, Kawaoka Y, Yotsuyanagi H.
    Previous Omicron infection may be protective against reinfection with Omicron variant BA.5 for at least 5 months.
    Clin Microbiol Infect 29(1):120-121, 2023.
29. Meng F, Yang H, Qu Z, Chen Y, Zhang Y, Zhang Y, Liu L, Zeng X, Li C, Kawaoka Y, Chen H.　
    A Eurasian avian-like H1N1 swine influenza reassortant virus became pathogenic and highly transmissible due to mutations in its PA gene. Proc Natl Acad Sci U S A.
    119(34):e2203919119, 2022.
30. Riemersma KK, Haddock LA 3rd, Wilson NA, Minor N, Eickhoff J, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian A, Florek KR, Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O'Connor DH, Friedrich TC, Grande KM.
    Shedding of infectious SARS-CoV-2 despite vaccination.
    PLoS Pathog 18(9):e1010876, 2022.
31. Suthar MS, Arunachalam PS, Hu M, Reis N, Trisal M, Raeber O, Chinthrajah S, Davis-Gardner ME, Manning K, Mudvari P, Boritz E, Godbole S, Henry AR, Douek DC, Halfmann P, Kawaoka Y, Boyd SD, Davis MM, Zarnitsyna VI, Nadeau K, Pulendran B.
    Durability of immune responses to the BNT162b2 mRNA vaccine.
    Med (N Y) 3(1):25-27, 2022.
32. Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y.
    Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents.
    Nature 612(7940):540-545, 2022.
33. Ohta M, Kambayashi Y, Mita H, Kuroda T, Bannai H, Tsujimura K, Yamanaka T, Garvey M, Cullinane A, Yamayoshi S, Kawaoka Y, Nemoto M.
    Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses.
    Vaccine 40(44):6362-6366, 2022.
34. Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Okuda M, Kawaoka Y.
    A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases.
    Nat Commun 13(1):6602, 2022.
35. Eiden J, Fierro C, Schwartz H, Adams M, Ellis KJ, Aitchison R, Herber R, Hatta Y, Marshall D, Moser MJ, Belshe R, Greenberg H, Coelingh K, Kawaoka Y, Neumann G, Bilsel P.
    Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies In Adults.
    J Infect Dis 227(1):103-112, 2022.
36. Takashita E, Yamayoshi S, Halfmann P, Wilson N, Ries H, Richardson A, Bobholz M, Vuyk W, Maddox R, Baker DA, Friedrich TC, O'Connor DH, Uraki R, Ito M, Sakai-Tagawa Y, Adachi E, Saito M, Koga M, Tsutsumi T, Iwatsuki-Horimoto K, Kiso M, Yotsuyanagi H, Watanabe S, Hasegawa H, Imai M, Kawaoka Y.
    In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.
    N Engl J Med 387(22):2094-2097, 2022.
37. Halfmann PJ, Frey SJ, Loeffler K, Kuroda M, Maemura T, Armbrust T, Yang JE, Hou YJ, Baric R, Wright ER, Kawaoka Y, Kane RS.
    Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. EBioMedicine.
    86:104341, 2022.
38. Takeshita M, Fukuyama H, Kamada K, Matsumoto T, Makino-Okamura C, Uchikubo-Kamo T, Tomabechi Y, Hanada K, Moriyama S, Takahashi Y, Ishigaki H, Nakayama M, Nguyen CT, Kitagawa Y, Itoh Y, Imai M, Maemura T, Furusawa Y, Ueki H, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Kawaoka Y, Shirouzu M, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T; Keio Donner Project.
    Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.
    iScience 25(12):105596. doi: 10.1016/j.isci.2022.105596. 2022.
39. Murakami S, Kitamura T, Matsugo H, Kamiki H, Oyabu K, Sekine W, Takenaka-Uema A, Sakai-Tagawa Y, Kawaoka Y, Horimoto T.
    Isolation of Bat Sarbecoviruses, Japan.
    Emerg Infect Dis 28(12):2500-2503, 2022.
40. Boon ACM, Darling TL, Halfmann PJ, Franks J, Webby RJ, Barouch DH, Port JR, Munster VJ, Diamond MS, Kawaoka Y.
    Reduced airborne transmission of SARS-CoV-2 BA.
    1 Omicron virus in Syrian hamsters. PLoS Pathog. 18(12):e1010970, 2022.
41. Sarawar S, Gabaglia CR, Sanchez A, Hatta Y, Dias P, Neumann G, Kawaoka Y, Bilsel P.
    Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice.　
    Vaccines (Basel). 10(12):2131, 2022.
42. Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann P, Kawaoka Y.
    Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.
    N Engl J Med 23(1):30-32, 2023.
43. Uraki R, Ito M, Furusawa Y, Yamayoshi S, Iwatsuki-Horimoto K, Adachi E, Saito M, Koga M, Tsutsumi T, Yamamoto S, Otani A, Kiso M, Sakai-Tagawa Y, Ueki H, Yotsuyanagi H, Imai M, Kawaoka Y.
    Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB.
    Lancet Infect Dis 23(1):30-32, 2023.
44. Chiba S, Hatta M, Pattinson D, Yasuhara A, Neumann G, Kawaoka Y. Ferret model to mimic the sequential exposure of humans to historical H3N2 influenza viruses.
    Vaccine 41(2):590-597, 2023.
45. Chen S, Quan DH, Sam G, Ozberk V, Wang XT, Halfmann P, Pandey M, Good MF, Kawaoka Y, Britton WJ, Rehm BHA.
    Assembly of Immunogenic Protein Particles toward Advanced Synthetic Vaccines.
    Small 19(8):e2205819, 2023.
46. Takashita E, Watanabe S, Hasegawa H, Kawaoka Y.
    Are twindemics occurring?Influenza Other Respir Viruses 17(1):e13090, 2023.　
47. Iwatsuki-Horimoto K, Ueki H, Ito M, Nagasawa S, Hirata Y, Hashizume K, Ushiwata K, Iwase H, Makino Y, Ushiku T, Akitomi S, Imai M, Saitoh H, Kawaoka Y.
    SARS-CoV-2 Transmission from Virus-Infected Dead Hamsters.
    mSphere 8(1):e0041122, 2023.
48. Saitoh H, Sakai-Tagawa Y, Nagasawa S, Torimitsu S, Kubota K, Hirata Y, Iwatsuki-Horimoto K, Motomura A, Ishii N, Okaba K, Horioka K, Abe H, Ikemura M, Rokutan H, Hinata M, Iwasaki A, Yasunaga Y, Nakajima M, Yamaguchi R, Tsuneya S, Kira K, Kobayashi S, Inokuchi G, Chiba F, Hoshioka Y, Mori A, Yamamoto I, Nakagawa K, Katano H, Iida S, Suzuki T, Akitomi S, Hasegawa I, Ushiku T, Yajima D, Iwase H, Makino Y, Kawaoka Y.
    High titers of infectious SARS-CoV-2 in COVID-19 corpses.
    Int J Infect Dis129:103-109, 2023.
49. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann P, Pekosz A, Kawaoka Y.
    Antiviral and Bivalent Vaccine Efficacy against an Omicron XBB.1.5 isolate.
    Lancet Inf Dis 23(4):402-403, 2023.
50. Mahita J, Ha B, Gambiez A, Schendel SL, Li H, Hastie KM, Dennison SM, Li K, Kuzmina N, Periasamy S, Bukreyev A, Munt JE, Osei-Twum M, Atyeo C, Overton JA, Vita R, Guzman-Orozco H, Mendes M, Kojima M, Halfmann PJ, Kawaoka Y, Alter G, Gagnon L, Baric RS, Tomaras GD, Germann T, Bedinger D, Greenbaum JA, Saphire EO, Peters B.
    Coronavirus Immunotherapeutic Consortium Database.
    Database (Oxford) 2023:baac112, 2023.
51. Nakayama T, Azegami T, Kiso M, Imai M, Uraki R, Hayashi K, Hishikawa A, Yoshimoto N, Nakamichi R, Sugita-Nishimura E, Yoshida-Hama E, Kawaoka Y, Itoh H.
    Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection.
    Sci Rep 13(1):3103, 2023.
52. Braun KM, Haddock Iii LA, Crooks CM, Barry GL, Lalli J, Neumann G, Watanabe T, Imai M, Yamayoshi S, Ito M, Moncla LH, Koelle K, Kawaoka Y, Friedrich TC.
    Avian H7N9 influenza viruses are evolutionarily constrained by stochastic processes during replication and transmission in mammals.
    Virus Evol 9(1):vead004, 2023.
53. McLean HQ, Petrie JG, Hanson KE, Meece JK, Rolfes MA, Sylvester GC, Neumann G, Kawaoka Y, Belongia EA.
    Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness - Wisconsin, October 2022-February 2023.
    MMWR Morb Mortal Wkly Rep 72(8):201-205, 2023.
54. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H.
    Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.
    Nat Commun 2023 Feb 25;14(1):1076, 2023.
55. Soga T, Duong C, Pattinson D, Sakai-Tagawa Y, Tokita A, Izumida N, Nishino T, Hagiwara H, Wada N, Miyamoto Y, Kuroki H, Hayashi Y, Seki M, Kasuya N, Koga M, Adachi E, Iwatsuki-Horimoto K, Yotsuyanagi H, Yamayoshi S, Kawaoka Y.
    Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018-2019 and 2019-2020 Influenza Seasons in Japan.
    Viruses15(2):535, 2023.
56. Changrob S, Halfmann PJ, Liu H, Torres JL, McGrath JJC, Ozorowski G, Li L, Wilbanks GD, Kuroda M, Maemura T, Huang M, Zheng NY, Turner HL, Erickson SA, Fu Y, Yasuhara A, Singh G, Monahan B, Mauldin J, Srivastava K, Simon V, Krammer F, Sather DN, Ward AB, Wilson IA, Kawaoka Y, Wilson PC.
    Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct Omicron subvariants.
    J Clin Invest 133(8):e166844, 2023.
57. Petrie JG, King JP, McClure DL, Rolfes MA, Meece JK, Pattinson D, Neumann G, Kawaoka Y, Belongia EA, McLean HQ.
    Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022.
    Influenza Other Respir Viruses17(3):e13104, 2023.
58. Bramer LM, Hontz RD, Eisfeld AJ, Sims AC, Kim YM, Stratton KG, Nicora CD, Gritsenko MA, Schepmoes AA, Akasaka O, Koga M, Tsutsumi T, Nakamura M, Nakachi I, Baba R, Tateno H, Suzuki S, Nakajima H, Kato H, Ishida K, Ishii M, Uwamino Y, Mitamura K, Paurus VL, Nakayasu ES, Attah IK, Letizia AG, Waters KM, Metz TO, Corson K, Kawaoka Y, Gerbasi VR, Yotsuyanagi H, Iwatsuki-Horimoto K.
    Multi-omics of NET formation and correlations with CNDP1, PSPB, and L-cystine levels in severe and mild COVID-19 infections.
    Heliyon 9(3):e13795, 2023.
59. Furusawa Y, Yamayoshi S, Kawaoka Y.
    The accuracy of reverse genetics systems for SARS-CoV-2: Circular polymerase extension reaction versus bacterial artificial chromosome.
    Influenza Other Respir Viruses17(3):e13109, 2023.
60. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y.
    Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
    Nat Commun 14(1):1620, 2023.
61. Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Sakai-Tagawa Y, Furusawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kashima Y, Kikuchi T, Yotsuyanagi H, Suzuki Y, Kawaoka Y.
    Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.Lancet Infect Dis 23(5): 525-526, 2023
62. Tamura D, Kawaoka Y. Omicron proliferation in the nasal cavity may explain its high infectivity.
    J Infect 86(6): 584-587, 2023

口頭・ポスター発表－国際学会・研究会

1. 河岡義裕、Addressing the threat of emerging viral infections、The 1st International Symposium of CiDER on Microbiology and Immunology、2022/1/11
2. 河岡義裕、Advances in our Understanding of SARS-CoV-2、OPTION Ⅺ、2022/9/22
3. 河岡義裕、Imaging analysis of RNA virus infection、UK G2P seminar (online)、2022/12/20
4. 河岡義裕、Imaging analysis of RNA virus infection、US CDC Science Day (online)、2023/1/13
5. 河岡義裕、SARS-CoV-2：最新の知見、第15回NCGM国際感染症フォーラム、2023/1/18

口頭・ポスター発表－国内学会・研究会

1. 河岡義裕、新興感染症の征圧を目指して、日本小児科学会北海道地方会第313回例会、2022/2/20
2. 河岡義裕、新興感染症の征圧を目指して、日本薬学会第142回学術集会、2022/3/27
3. 河岡義裕、新型コロナウイルス感染症：これまでにわかったこと、動物実験関係者連絡協議会第10回シンポジウム、2022/4/16
4. 河岡義裕、新興感染症の征圧を目指して、藤田医科大学創立記念講演、2022/6/4
5. 河岡義裕、新興感染症の征圧を目指して、静岡県獣医師講演 県民公開講座、2022/6/12
6. 河岡義裕、新型コロナウイルス感染症：これまでにわかったこと、JHシンポジウム、2022/11/2
7. 河岡義裕、新興感染症の征圧を目指して、第21回アジア獣医師会連合大会、2022/11/11
8. 河岡義裕、Addressing the threat of emerging viral infections、水谷糖質科学振興財団シンポジウム、2022/11/25
9. 河岡義裕、新興感染症の征圧を目指して、第51回日本免疫学会、2022/12/7
10. 河岡義裕、新興感染症の征圧を目指して、兵庫医科大学講演、2023/1/31
11. 今井正樹、ウイルス感染症研究におけるハムスターの有用性、第69回日本実験動物学会総会、2022/5/18、仙台
12. 植木紘史、2光子生体イメージングでみるウイルス感染肺、第4回B6JAged研究会、2022/11/22、東京
13. 浦木隆太、動物モデルを用いた新型コロナウイルス・オミクロン株に対する抗体薬と抗ウイルス薬の効果の検証、第69回ウイルス学会学術集会
14. 浦木隆太、Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron variants in animal models、第51回日本免疫学会学術集会
15. 山吉誠也、安原敦洋、木曽真紀、坂井（田川）優子、奥田萌、河岡義裕、AおよびB型インフルエンザウイルスのNA蛋白質を認識する交叉反応性中和ヒトモノクローナル抗体の性状解析、第69回日本ウイルス学会学術集会、2022/11/13-15、兵庫
16. 古澤夢梨、木曽真紀、今井正樹、山吉誠也、河岡義裕、新型コロナウイルスデルタ株のスパイク蛋白質の681位のアルギニンおよび950位のアスパラギン酸がウイルス性状に及ぼす影響、第69回日本ウイルス学会学術集会、2022/11/13、長崎
17. 植木紘史、動物モデルを用いて新型コロナウイルス感染症（COVID-19）の病態メカニズムの解明、2022　NCGM 夏季リトリート、2022/7/14-15、東京
18. 植木紘史、Wang I-Hsuan、神谷亘、河岡義裕、SARS-CoV-2感染肺の2光子生体肺イメージング解析、第69回日本ウイルス学会、2022/7/13-15、長崎

著書・総説

総説－和文

1. 山本真也、山吉誠也、河岡義裕 2022 SARS-CoV-2変異株と罹患時の臨床的特徴 臨床と微生物 49(6): 659-664.
2. 古澤夢梨、山吉誠也 2022 コロナウイルスの変異ウイルスについて インフルエンザ［その他の呼吸器感染症］23(3): 25-30.
3. 古澤夢梨、山吉誠也、河岡義裕 2022 ウイルス学的特徴からの考察：新型コロナウイルスとかぜコロナウイルスの比較を含めて 呼吸器ジャーナル 70(3): 329-337.
4. 坂井（田川）優子、山吉誠也、河岡義裕 2022 COVID-19抗原検査キットの感度比較 インフルエンザ［その他の呼吸器感染症］23(1): 15-22.
5. 浦木隆太、山吉誠也、河岡義裕 2022 COVID-19の変異ウイルスについて インフルエンザ［その他の呼吸器感染症］23(1): 37-44.
6. 古澤夢梨、山吉誠也、河岡義裕 2022 感染症ワクチン総論 日本老年医学会雑誌 59: 16-21.
7. 安原敦洋、山吉誠也、河岡義裕 2022 新型コロナウイルスワクチンの変異ウイルスに対する有効性と懸念される副作用 広島県内科会会誌 22: 10-14.
8. 植木紘史、河岡義裕、呼吸器系感染症の生体イメージング　―2光子生体イメージングでみるウイルス感染肺―、医学のあゆみ 286 (5), 455-460
9. 浦木隆太、河岡義裕、COVID-19の病態におけるウイルス側の要因、2023年3月号
10. 浦木隆太、今井正樹、河岡義裕、SARS-CoV2オミクロン/BA.2変異株の特徴および抗ウイルス薬に対する感受性、臨床免疫・アレルギー科. 第79巻第1号
11. 古澤夢梨、河岡 義裕、ウイルス自壊説について、インフルエンザVol.23 No.4、p.275-278、 2022年12月
12. 古澤夢梨、河岡義裕、インフルエンザの流行が2年間ありませんが、今後どのようになるのでしょうか、インフルエンザVol.23 No.4、p.285、2022年12月